(Q73432099)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12764398%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

title

ALLHAT: a saga of missed opportunities (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12764398%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

author name string

McInnes GT

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12764398%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

publication date

1 June 2003

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12764398%20AND%20SRC:MED&resulttype=core&format=json

Journal of Human Hypertension

3 November 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12764398%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

volume

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12764398%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12764398%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

page(s)

373-377

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12764398%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/sj.jhh.1001564

3 November 2019

exact match

0 references

cites work

Blood pressure, antihypertensive drug treatment and the risks of stroke and of coronary heart disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001564

7 January 2021

How bad are diuretic-induced hypokalemia and hypercholesterolemia?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001564

7 January 2021

Antihypertensive and adverse biochemical effects of bendrofluazide

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001564

7 January 2021

Hypertension and coronary risk: possible adverse effects of antihypertensive drugs

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001564

7 January 2021

Beta blockade during and after myocardial infarction: an overview of the randomized trials

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001564

7 January 2021

Blood pressure, stroke, and coronary heart disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001564

7 January 2021

Health outcomes associated with antihypertensive therapies used as first-line agents. A systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001564

7 January 2021

Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001564

7 January 2021

Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001564

7 January 2021

Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT).

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001564

7 January 2021

Randomised trial of effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001564

7 January 2021

Early prediction of severity in acute pancreatitis by urinary trypsinogen activation peptide: a multicentre study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001564

7 January 2021

Health outcomes associated with calcium antagonists compared with other first-line antihypertensive therapies: a meta-analysis of randomised controlled trials

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001564

7 January 2021

Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001564

7 January 2021

Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001564

7 January 2021

Cardiovascular protection and blood pressure reduction: a meta-analysis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001564

7 January 2021

Effects of Calcium-Channel Blockade in Older Patients with Diabetes and Systolic Hypertension

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001564

7 January 2021

Guidelines for management of hypertension: report of the third working party of the British Hypertension Society

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001564

7 January 2021

Regional and racial differences in response to antihypertensive medication use in a randomized controlled trial of men with hypertension in the United States. Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001564

7 January 2021

Pathophysiology and treatment implications of hypertension in the African-American population

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001564

7 January 2021

Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT).

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001564

7 January 2021

Racial differences in response to therapy for heart failure: analysis of the vasodilator-heart failure trials. Vasodilator-Heart Failure Trial Study Group

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001564

7 January 2021

Lesser response to angiotensin-converting-enzyme inhibitor therapy in black as compared with white patients with left ventricular dysfunction

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001564

7 January 2021

Calcium-channel blockers for hypertension--uncertainty continues

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001564

7 January 2021

Nifedipine. Dose-related increase in mortality in patients with coronary heart disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001564

7 January 2021

Relationship of antihypertensive treatment regimens and change in blood pressure to risk for heart failure in hypertensive patients randomly assigned to doxazosin or chlorthalidone: further analyses from the Antihypertensive and Lipid-Lowering treat

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001564

7 January 2021

Cardiotoxicity and diuretics: much speculation--little substance

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001564

7 January 2021